HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $382,000 | +5.9% | 10,000 | 0.0% | 0.02% | +4.8% |
| Q2 2023 | $360,700 | -5.6% | 10,000 | 0.0% | 0.02% | -16.0% |
| Q1 2023 | $381,900 | -32.9% | 10,000 | 0.0% | 0.02% | -34.2% |
| Q4 2022 | $569,000 | +44.1% | 10,000 | 0.0% | 0.04% | +35.7% |
| Q3 2022 | $395,000 | -10.2% | 10,000 | 0.0% | 0.03% | -6.7% |
| Q2 2022 | $440,000 | +10.3% | 10,000 | 0.0% | 0.03% | +36.4% |
| Q1 2022 | $399,000 | -0.7% | 10,000 | 0.0% | 0.02% | +22.2% |
| Q4 2021 | $402,000 | -1.2% | 10,000 | 0.0% | 0.02% | -14.3% |
| Q3 2021 | $407,000 | -10.4% | 10,000 | 0.0% | 0.02% | -4.5% |
| Q2 2021 | $454,000 | +8.9% | 10,000 | 0.0% | 0.02% | 0.0% |
| Q1 2021 | $417,000 | -2.3% | 10,000 | 0.0% | 0.02% | -15.4% |
| Q4 2020 | $427,000 | +62.4% | 10,000 | 0.0% | 0.03% | +18.2% |
| Q3 2020 | $263,000 | -1.9% | 10,000 | 0.0% | 0.02% | -12.0% |
| Q2 2020 | $268,000 | +48.9% | 10,000 | 0.0% | 0.02% | +13.6% |
| Q1 2020 | $180,000 | +1.7% | 10,000 | 0.0% | 0.02% | +57.1% |
| Q4 2019 | $177,000 | +14.2% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $155,000 | -9.9% | 10,000 | 0.0% | 0.01% | -12.5% |
| Q2 2019 | $172,000 | +6.8% | 10,000 | 0.0% | 0.02% | +14.3% |
| Q1 2019 | $161,000 | +10.3% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q4 2018 | $146,000 | -19.8% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $182,000 | +7.7% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q2 2018 | $169,000 | -13.8% | 10,000 | 0.0% | 0.01% | -17.6% |
| Q1 2018 | $196,000 | -3.4% | 10,000 | 0.0% | 0.02% | 0.0% |
| Q4 2017 | $203,000 | +16.7% | 10,000 | 0.0% | 0.02% | +13.3% |
| Q3 2017 | $174,000 | +35.9% | 10,000 | 0.0% | 0.02% | +25.0% |
| Q2 2017 | $128,000 | -1.5% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q1 2017 | $130,000 | +31.3% | 10,000 | 0.0% | 0.01% | +20.0% |
| Q4 2016 | $99,000 | -18.2% | 10,000 | 0.0% | 0.01% | -23.1% |
| Q3 2016 | $121,000 | +40.7% | 10,000 | 0.0% | 0.01% | +30.0% |
| Q2 2016 | $86,000 | -9.5% | 10,000 | 0.0% | 0.01% | -9.1% |
| Q1 2016 | $95,000 | -45.1% | 10,000 | 0.0% | 0.01% | -42.1% |
| Q4 2015 | $173,000 | +29.1% | 10,000 | 0.0% | 0.02% | +18.8% |
| Q3 2015 | $134,000 | -40.7% | 10,000 | 0.0% | 0.02% | -30.4% |
| Q2 2015 | $226,000 | +58.0% | 10,000 | 0.0% | 0.02% | +53.3% |
| Q1 2015 | $143,000 | +49.0% | 10,000 | 0.0% | 0.02% | +66.7% |
| Q4 2014 | $96,000 | +5.5% | 10,000 | 0.0% | 0.01% | +12.5% |
| Q3 2014 | $91,000 | -8.1% | 10,000 | 0.0% | 0.01% | +14.3% |
| Q2 2014 | $99,000 | -22.0% | 10,000 | 0.0% | 0.01% | -22.2% |
| Q1 2014 | $127,000 | -15.3% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q4 2013 | $150,000 | +36.4% | 10,000 | 0.0% | 0.01% | +28.6% |
| Q3 2013 | $110,000 | +39.2% | 10,000 | 0.0% | 0.01% | +75.0% |
| Q2 2013 | $79,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |